Assistant Professor, Internal Medicine, Ohio State University College of Medicine

Hematology

Dr. Yvonne A. Efebera is an expert in the field of Hematology. She attended Penn State College of Medicine. She has 1 awards "CMS Meaningful Use Stage 1 Certification". Yvonne Efebera is a published MD. She has 24 papers published. The most current publication "Atorvastatin for the Prophylaxis of Acute Graft vs. Host Disease (GVHD) in Patients Undergoing HLA-Matched Related Donor Hematopoietic Stem Cell Transplantation (HSCT)." She is registered with Medicare.

Publications

---

• Atorvastatin for the Prophylaxis of Acute Graft vs. Host Disease (GVHD) in Patients Undergoing HLA-Matched Related Donor Hematopoietic Stem Cell Transplantation (HSCT).
• A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem Cell transpl...
• Lower dose of antithymocyte globulin does not increase Graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem ce...
• The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for Lymphoma and multiple myeloma.
• A Phase 1 Trial of Single Agent Reolysin in Patients with Relapsed Multiple Myeloma.
• It is time to move forward with Waldenström!
• Circulating miRNA markers show promise as new prognosticators for multiple Myeloma.
• Novel gelsolin variant as the cause of nephrotic syndrome and renal amyloidosis in a large kindred.
• Elotuzumab directly enhances NK Cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK Cell function complementing ADCC.
• A phase I trial of flavopiridol in relapsed multiple Myeloma.
• Characterization of Multiple Myeloma Vesicles by Label-Free Relative Quantitation.
• Early versus delayed autologous stem Cell transplant in patients receiving novel therapies for multiple myeloma.
• A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple Myeloma.
• Reduced-intensity allogeneic hematopoietic stem Cell transplantation for relapsed multiple myeloma.
• Long-Term Therapy with Lenalidomide in a Patient with POEMS Syndrome.
• Improved accuracy of Acute graft-versus-host disease staging among multiple centers.
• Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem Cell tra...
• CD40 Ligand-activated, antigen-specific B Cells are comparable to mature dendritic Cells in presenting protein antigens and major histocompatibility complex class I- a...
• IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer Cell versus multiple myeloma effect.
• Strong transthyretin immunostaining: potential pitfall in cardiac amyloid typing.
• Complete response to thalidomide and dexamethasone in a patient with necrobiotic xanthogranuloma associated with monoclonal gammopathy: a case report and review of the...
• Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic Cell transplantation following fludarabine, busulfan-based re...
• The PD-1/PD-L1 axis modulates the natural killer Cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.

Schools

---

• Pennsylvania State University College Of Medicine

• Cleveland Clinic Found

• Boston University Mc

Procedures Preformed

---

• Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
• HPC Transplantation (Stem Cell Transplant)
• Plasmapheresis
• Thoracentesis

Conditions Treated

---

• Acute Leukemia
• Anemia
• Central Nervous System Lymphoma
• Chronic Myeloid Leukemia (CML)
• View All

Doctors Specialties

---

• Medical Oncology
• Oncology
• Hematology

Accepted Insurances

---

Awards

---

• CMS Meaningful Use Stage 1 Certification

Education

---

• Boston University Medical Center
• Cleveland Clinic Foundation
• Penn State College of Medicine

Hospital

---

• Ohio State University Wexner Medical Center

Drug Facts

---

NPI NUMBER		1285612986
NPPES Provider LastName		EFEBERA
NPPES Provider FirstName		YVONNE
NPPES Provider ZIPCode		432101240
NPPES Provider State		OH
Specialty Description		Hematology/Oncology
Total Claim Count		544.0
Distinct Opioid Count		3.0
Opioid Claim Count		96.0
Percent Opioid Claims		17.65

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1285612986
Last Name Of The Provider	EFEBERA
First Name Of The Provider	YVONNE
View All

Similar Doctors

---

	Dr. Neil C. Dunavin, MD This Doctor is OpenDoctor Recommended.
	Dr. Peter J. Kourlas, MD This Doctor is OpenDoctor Recommended.
	Dr. Spero R. Cataland, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Manisha H. Shah, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Christopher S. George, MD This Doctor is OpenDoctor Recommended.
	Dr. Erin M. Olson, MD This Doctor is OpenDoctor Recommended.
	Dr. Brent C. Behrens, MD This Doctor is OpenDoctor Recommended.
	Dr. Mary E. Wissel, MD This Doctor is OpenDoctor Recommended.
	Dr. Sumithira Vasu, MD This Doctor is OpenDoctor Recommended.
	Dr. Sarah A. Wall, MD

---

Doctor Directory | TOS | twitter | FB | Angel | blog